Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  4/21/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 4/21/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura.
Status: Enrolling
Updated:  5/3/2016
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura.
Status: Enrolling
Updated: 5/3/2016
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura.
Status: Enrolling
Updated:  5/3/2016
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura.
Status: Enrolling
Updated: 5/3/2016
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)
An Open Label, Two-part, Phase I/Randomized Phase II Study in Subjects With Relapsed/Refractory Multiple Myeloma to Determine a Dose of Afuresertib for Administration in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of Afuresertib With Carfilzomib Compared With Carfilzomib Alone (Part 2)
Status: Enrolling
Updated:  5/3/2016
Novartis Investigative Site
mi
from
Cary, NC
A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)
An Open Label, Two-part, Phase I/Randomized Phase II Study in Subjects With Relapsed/Refractory Multiple Myeloma to Determine a Dose of Afuresertib for Administration in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of Afuresertib With Carfilzomib Compared With Carfilzomib Alone (Part 2)
Status: Enrolling
Updated: 5/3/2016
Novartis Investigative Site
mi
from
Cary, NC
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
RMCC
mi
from
Denver, CO
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
RMCC
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
Emory
mi
from
Atlanta, GA
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
Emory
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
Rush
mi
from
Chicago, IL
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
Rush
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
IU
mi
from
Indianapolis, IN
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
IU
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
HUMC
mi
from
Hackensack, NJ
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
HUMC
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
Cornell
mi
from
New York City, NY
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
Cornell
mi
from
New York City, NY
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
OSU
mi
from
Columbus, OH
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
OSU
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
SCRI
mi
from
Nashville, TN
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
SCRI
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  5/5/2016
MDACC
mi
from
Houston, TX
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 5/5/2016
MDACC
mi
from
Houston, TX
Click here to add this to my saved trials
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status: Enrolling
Updated:  5/5/2016
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status: Enrolling
Updated: 5/5/2016
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status: Enrolling
Updated:  5/5/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status: Enrolling
Updated: 5/5/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status: Enrolling
Updated:  5/5/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status: Enrolling
Updated: 5/5/2016
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status: Enrolling
Updated:  5/5/2016
Medical College of Wisconsin
mi
from
Milwaukee, WI
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status: Enrolling
Updated: 5/5/2016
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status: Enrolling
Updated:  5/5/2016
The Mayo Clinic
mi
from
Rochester, MN
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies
Status: Enrolling
Updated: 5/5/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Rapid Radiation Therapy for Painful Osseous Metastatic Disease
Phase II Pilot Single Arm Prospective Clinical Trial of Rapid Institution of Helical TomoTherapy-based Radiation Therapy for Patients With Painful Osseous Metastatic Disease
Status: Enrolling
Updated:  5/10/2016
University of Virginia
mi
from
Charlottesville, VA
Rapid Radiation Therapy for Painful Osseous Metastatic Disease
Phase II Pilot Single Arm Prospective Clinical Trial of Rapid Institution of Helical TomoTherapy-based Radiation Therapy for Patients With Painful Osseous Metastatic Disease
Status: Enrolling
Updated: 5/10/2016
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)
Phase 1 Study of Topical Beta Blocker to Prevent the Proliferative Stage of Infantile Hemangioma
Status: Enrolling
Updated:  5/10/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)
Phase 1 Study of Topical Beta Blocker to Prevent the Proliferative Stage of Infantile Hemangioma
Status: Enrolling
Updated: 5/10/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab
Status: Enrolling
Updated:  5/11/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab
Status: Enrolling
Updated: 5/11/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
Status: Enrolling
Updated:  5/13/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Ponatinib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
Status: Enrolling
Updated: 5/13/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Clinical and Economic Implications of Genetic Testing for Warfarin Management
The Hospital and Economics CERT: Project 1: The Clinical and Economic Implications of Genetic Testing for Warfarin Management
Status: Enrolling
Updated:  5/17/2016
University of Chicago
mi
from
Chicago, IL
Clinical and Economic Implications of Genetic Testing for Warfarin Management
The Hospital and Economics CERT: Project 1: The Clinical and Economic Implications of Genetic Testing for Warfarin Management
Status: Enrolling
Updated: 5/17/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia
SCOR in Targeted Therapies for Infant Leukemia Project 3: Targeting FLT3 in Infant Leukemia
Status: Enrolling
Updated:  5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia
SCOR in Targeted Therapies for Infant Leukemia Project 3: Targeting FLT3 in Infant Leukemia
Status: Enrolling
Updated: 5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Click here to add this to my saved trials
Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia
Observational - NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia
Status: Enrolling
Updated:  5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia
Observational - NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia
Status: Enrolling
Updated: 5/17/2016
Children's Oncology Group
mi
from
Monrovia, CA
Click here to add this to my saved trials
Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia
Genetic Predictors of AML Treatment Response
Status: Enrolling
Updated:  5/17/2016
Children's Oncology Group
mi
from
Philadelphia, PA
Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia
Genetic Predictors of AML Treatment Response
Status: Enrolling
Updated: 5/17/2016
Children's Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated:  5/23/2016
University of Florida
mi
from
Gainesville, FL
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated: 5/23/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated:  5/23/2016
University of Chicago
mi
from
Chicago, IL
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated: 5/23/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated:  5/23/2016
Tufts - New England Medical Center
mi
from
Boston, MA
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated: 5/23/2016
Tufts - New England Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated:  5/23/2016
Kansas City Cancer Center
mi
from
Kansas City, MO
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated: 5/23/2016
Kansas City Cancer Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated:  5/23/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated: 5/23/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated:  5/23/2016
Texas Transplant
mi
from
San Antonio, TX
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated: 5/23/2016
Texas Transplant
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated:  5/23/2016
Royal Brisbane Hospital
mi
from
Brisbane,
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
Status: Enrolling
Updated: 5/23/2016
Royal Brisbane Hospital
mi
from
Brisbane,
Click here to add this to my saved trials
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated:  5/23/2016
University of Florida
mi
from
Gainesville, FL
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated: 5/23/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated:  5/23/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated: 5/23/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated:  5/23/2016
Weill Medical College of Cornell University
mi
from
New York, NY
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated: 5/23/2016
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated:  5/23/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated: 5/23/2016
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated:  5/23/2016
Leukemia and Bone Marrow Transplant Center - Avera Cancer Institute
mi
from
Sioux Falls, SD
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated: 5/23/2016
Leukemia and Bone Marrow Transplant Center - Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated:  5/23/2016
Royal Brisbane Women's Hospital
mi
from
Brisbane,
Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease
Status: Enrolling
Updated: 5/23/2016
Royal Brisbane Women's Hospital
mi
from
Brisbane,
Click here to add this to my saved trials
Electronic Catheter Stethoscope
Use of the Electronic Catheter Stethoscope for the Detection of Urinary Tract Injury During Gynecologic Surgery
Status: Enrolling
Updated:  5/26/2016
Women's Center Operating Rooms at the Tampa General Hospital
mi
from
Tampa, FL
Electronic Catheter Stethoscope
Use of the Electronic Catheter Stethoscope for the Detection of Urinary Tract Injury During Gynecologic Surgery
Status: Enrolling
Updated: 5/26/2016
Women's Center Operating Rooms at the Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Pacific Cancer Care
mi
from
Monterey, CA
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Pacific Cancer Care
mi
from
Monterey, CA
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Maine Center for Cancer Medicine
mi
from
Scarborough, ME
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Maine Center for Cancer Medicine
mi
from
Scarborough, ME
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
Massachusetts General Hospital
mi
from
Boston, MA
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
The West Clinic, PC
mi
from
Southaven, MS
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
The West Clinic, PC
mi
from
Southaven, MS
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
New York Oncology, Hematology, P.C.
mi
from
Hudson, NY
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
New York Oncology, Hematology, P.C.
mi
from
Hudson, NY
Click here to add this to my saved trials
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/1/2016
The West Clinic, PC
mi
from
Memphis, TN
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/1/2016
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials